Baseline characteristics of 701 MDS patients that underwent allogeneic HCT between 2002 and 2006 and reported to the CIBMTR
| Variable . | MRD . | 8/8 MUD . | 7/8 MUD . | P* . |
|---|---|---|---|---|
| N | 176 | 413 | 112 | |
| Age | 54 (22-72) | 53 (22-78) | 54 (26-72) | .19† |
| Age grouped | .06 | |||
| 20-29 | 6 (3) | 27 (7) | 3 (3) | |
| 30-39 | 16 (9) | 64 (15) | 8 (7) | |
| 40-49 | 45 (26) | 97 (23) | 36 (32) | |
| 50-59 | 79 (45) | 160 (39) | 46 (41) | |
| ≥60 | 30 (17) | 65 (16) | 19 (17) | |
| Gender | .07 | |||
| Male | 105 (60) | 245 (59) | 80 (71) | |
| Female | 70 (40) | 168 (41) | 32 (29) | |
| Missing | 1 (1) | 0 | 0 | |
| Karnofsky score | <.001 | |||
| ≥90 | 101 (57) | 229 (55) | 72 (64) | |
| <90 | 68 (39) | 119 (29) | 30 (27) | |
| Missing | 7 (4) | 65 (16) | 10 (9) | |
| Race | .053 | |||
| White | 156 (89) | 392 (95) | 106 (95) | |
| Black | 8 (5) | 8 (2) | 1 (1) | |
| Asian | 8 (5) | 3 (1) | 2 (2) | |
| Others-American Indian-Native Hawaiian | 1 (1) | 2 (<1) | 1 (1) | |
| Missing | 3 (2) | 8 (2) | 2 (2) | |
| Bone marrow blast percent at transplant‡ | .41 | |||
| ≤5% | 76 (57) | 224 (63) | 62 (61) | |
| >5% | 57 (43) | 128 (36) | 40 (39) | |
| FAB at diagnosis§ | .31 | |||
| Refractory anemia | 47 (28) | 108 (26) | 25 (22) | |
| Refractory anemia with ringed sideroblasts | 10 (6) | 21 (5) | 8 (7) | |
| Refractory Anemia with Excess Blasts | 72 (43) | 154 (37) | 43 (39) | |
| Refractory anemia with excess blasts in transformation | 4 (2) | 15 (4) | 5 (4) | |
| Chronic myelomonocytic leukemia | 15 (9) | 42 (10) | 15 (13) | |
| MDS/MPD not otherwise specified | 18 (11) | 73 (17) | 15 (13) | |
| MDS disease status at transplant | .37 | |||
| Early | 58 (33) | 138 (33) | 33 (29) | |
| Advanced | 115 (65) | 264 (64) | 79 (71) | |
| Missing | 3 (2) | 11 (3) | 0 | |
| Secondary MDS (therapy related) | <.001 | |||
| No | 125 (71) | 329 (80) | 86 (77) | |
| Yes | 28 (16) | 81 (20) | 22 (20) | |
| Missing | 23 (13) | 3 (1) | 4 (4) | |
| Cytogenetics|| | .37 | |||
| Favorable (normal, ch. 5 abnormal, ch. 20 abnormal) | 79 (51) | 159 (47) | 46 (52) | |
| Adverse (≥3 abnormal, ch. 7 abnormal) | 39 (25) | 113 (33) | 27 (31) | |
| Intermediate (all others) | 37 (24) | 70 (20) | 15 (17) | |
| IPSS at diagnosis | .26 | |||
| Low | 19 (10) | 29 (7) | 12 (10) | |
| Int-1 | 37 (21) | 129 (31) | 27 (24) | |
| Int-2 | 41 (23) | 80 (19) | 21 (19) | |
| High | 9 (5) | 23 (5) | 8 (7) | |
| Missing | 70 (40) | 152 (37) | 44 (39) | |
| WBC at diagnosis | .82 | |||
| Less then 3.2 ×10^9/L | 85 (48) | 187 (45) | 51 (46) | |
| Greater than 3.2 ×10^9/L | 72 (41) | 189 (46) | 49 (44) | |
| Missing | 19 (11) | 37 (9) | 12 (11) | |
| Interval between diagnosis and transplant | 6 (2-129) | 8 (1-194) | 10 (2-269) | <.001† |
| Donor age | 52 (18-75) | 33 (19-60) | 36 (19-218) | <.001† |
| Donor age | <.001 | |||
| Younger than 20 y | 2 (1) | 8 (2) | 3 (3) | |
| 20-29 | 4 (2) | 151 (37) | 26 (23) | |
| 30-39 | 17 (10) | 141 (34) | 46 (41) | |
| 40-49 | 52 (30) | 92 (22) | 28 (25) | |
| 50-59 | 69 (39) | 20 (5) | 8 (7) | |
| Older than 60 y | 30 (17) | 1 (<1) | 0 | |
| Missing | 2 (1) | 0 | 1 (1) | |
| Sex match | <.001 | |||
| M-M | 55 (31) | 196 (47) | 50 (45) | |
| M-F | 43 (25) | 110 (27) | 13 (12) | |
| F-M | 50 (29) | 49 (12) | 30 (27) | |
| F-F | 27 (15) | 58 (14) | 19 (17) | |
| Missing | 1 | 0 | 0 | |
| Cytomegalovirus match | <.001 | |||
| Pos-pos | 72 (41) | 65 (16) | 20 (18) | |
| Pos-neg | 16 (9) | 31 (8) | 15 (13) | |
| Neg-pos | 44 (25) | 151 (37) | 36 (32) | |
| Neg-neg | 34 (19) | 131 (32) | 34 (30) | |
| Not tested/inconclusive | 10 (6) | 35 (8) | 7 (6) | |
| Conditioning regimen intensity | <.001 | |||
| Myeloablative | 99 (56) | 246 (59) | 65 (58) | |
| Reduced intensity | 46 (26) | 119 (29) | 33 (29) | |
| Nonmyeloblative | 24 (15) | 47 (11) | 14 (13) | |
| Missing | 4 (2) | 1 (<1) | 0 | |
| Stem cell source | <.001 | |||
| Bone marrow | 14 (8) | 123 (30) | 21 (19) | |
| Peripheral blood | 162 (92) | 290 (70) | 91 (81) | |
| GVHD prophylaxis | <.001 | |||
| None | 1 (1) | 1 (<1) | 1 (1) | |
| FK506+MTX+-oth | 57 (32) | 198 (48) | 45 (40) | |
| FK506+-oth | 30 (17) | 63 (15) | 28 (25) | |
| CsA+MTX+-oth | 40 (23) | 91 (22) | 26 (23) | |
| CsA+-oth | 46 (26) | 50 (12) | 11 (10) | |
| Other | 2 (1) | 10 (2) | 1 (1) | |
| Anti-thymocyte globulin therapy | <.001 | |||
| No | 158 (90) | 306 (74) | 82 (73) | |
| Yes | 18 (10) | 107 (26) | 30 (27) | |
| Year of transplant | .01 | |||
| 2002 | 38 (22) | 47 (11) | 14 (13) | |
| 2003 | 23 (13) | 69 (17) | 22 (20) | |
| 2004 | 37 (21) | 81 (20) | 19 (17) | |
| 2005 | 44 (25) | 91 (22) | 32 (29) | |
| 2006 | 34 (19) | 125 (30) | 25 (22) | |
| Median (range) follow-up of survivors, mo | 50 (3-96) | 46 (6-87) | 39 (9-83) | |
| Total number died | 107 | 253 | 82 |
| Variable . | MRD . | 8/8 MUD . | 7/8 MUD . | P* . |
|---|---|---|---|---|
| N | 176 | 413 | 112 | |
| Age | 54 (22-72) | 53 (22-78) | 54 (26-72) | .19† |
| Age grouped | .06 | |||
| 20-29 | 6 (3) | 27 (7) | 3 (3) | |
| 30-39 | 16 (9) | 64 (15) | 8 (7) | |
| 40-49 | 45 (26) | 97 (23) | 36 (32) | |
| 50-59 | 79 (45) | 160 (39) | 46 (41) | |
| ≥60 | 30 (17) | 65 (16) | 19 (17) | |
| Gender | .07 | |||
| Male | 105 (60) | 245 (59) | 80 (71) | |
| Female | 70 (40) | 168 (41) | 32 (29) | |
| Missing | 1 (1) | 0 | 0 | |
| Karnofsky score | <.001 | |||
| ≥90 | 101 (57) | 229 (55) | 72 (64) | |
| <90 | 68 (39) | 119 (29) | 30 (27) | |
| Missing | 7 (4) | 65 (16) | 10 (9) | |
| Race | .053 | |||
| White | 156 (89) | 392 (95) | 106 (95) | |
| Black | 8 (5) | 8 (2) | 1 (1) | |
| Asian | 8 (5) | 3 (1) | 2 (2) | |
| Others-American Indian-Native Hawaiian | 1 (1) | 2 (<1) | 1 (1) | |
| Missing | 3 (2) | 8 (2) | 2 (2) | |
| Bone marrow blast percent at transplant‡ | .41 | |||
| ≤5% | 76 (57) | 224 (63) | 62 (61) | |
| >5% | 57 (43) | 128 (36) | 40 (39) | |
| FAB at diagnosis§ | .31 | |||
| Refractory anemia | 47 (28) | 108 (26) | 25 (22) | |
| Refractory anemia with ringed sideroblasts | 10 (6) | 21 (5) | 8 (7) | |
| Refractory Anemia with Excess Blasts | 72 (43) | 154 (37) | 43 (39) | |
| Refractory anemia with excess blasts in transformation | 4 (2) | 15 (4) | 5 (4) | |
| Chronic myelomonocytic leukemia | 15 (9) | 42 (10) | 15 (13) | |
| MDS/MPD not otherwise specified | 18 (11) | 73 (17) | 15 (13) | |
| MDS disease status at transplant | .37 | |||
| Early | 58 (33) | 138 (33) | 33 (29) | |
| Advanced | 115 (65) | 264 (64) | 79 (71) | |
| Missing | 3 (2) | 11 (3) | 0 | |
| Secondary MDS (therapy related) | <.001 | |||
| No | 125 (71) | 329 (80) | 86 (77) | |
| Yes | 28 (16) | 81 (20) | 22 (20) | |
| Missing | 23 (13) | 3 (1) | 4 (4) | |
| Cytogenetics|| | .37 | |||
| Favorable (normal, ch. 5 abnormal, ch. 20 abnormal) | 79 (51) | 159 (47) | 46 (52) | |
| Adverse (≥3 abnormal, ch. 7 abnormal) | 39 (25) | 113 (33) | 27 (31) | |
| Intermediate (all others) | 37 (24) | 70 (20) | 15 (17) | |
| IPSS at diagnosis | .26 | |||
| Low | 19 (10) | 29 (7) | 12 (10) | |
| Int-1 | 37 (21) | 129 (31) | 27 (24) | |
| Int-2 | 41 (23) | 80 (19) | 21 (19) | |
| High | 9 (5) | 23 (5) | 8 (7) | |
| Missing | 70 (40) | 152 (37) | 44 (39) | |
| WBC at diagnosis | .82 | |||
| Less then 3.2 ×10^9/L | 85 (48) | 187 (45) | 51 (46) | |
| Greater than 3.2 ×10^9/L | 72 (41) | 189 (46) | 49 (44) | |
| Missing | 19 (11) | 37 (9) | 12 (11) | |
| Interval between diagnosis and transplant | 6 (2-129) | 8 (1-194) | 10 (2-269) | <.001† |
| Donor age | 52 (18-75) | 33 (19-60) | 36 (19-218) | <.001† |
| Donor age | <.001 | |||
| Younger than 20 y | 2 (1) | 8 (2) | 3 (3) | |
| 20-29 | 4 (2) | 151 (37) | 26 (23) | |
| 30-39 | 17 (10) | 141 (34) | 46 (41) | |
| 40-49 | 52 (30) | 92 (22) | 28 (25) | |
| 50-59 | 69 (39) | 20 (5) | 8 (7) | |
| Older than 60 y | 30 (17) | 1 (<1) | 0 | |
| Missing | 2 (1) | 0 | 1 (1) | |
| Sex match | <.001 | |||
| M-M | 55 (31) | 196 (47) | 50 (45) | |
| M-F | 43 (25) | 110 (27) | 13 (12) | |
| F-M | 50 (29) | 49 (12) | 30 (27) | |
| F-F | 27 (15) | 58 (14) | 19 (17) | |
| Missing | 1 | 0 | 0 | |
| Cytomegalovirus match | <.001 | |||
| Pos-pos | 72 (41) | 65 (16) | 20 (18) | |
| Pos-neg | 16 (9) | 31 (8) | 15 (13) | |
| Neg-pos | 44 (25) | 151 (37) | 36 (32) | |
| Neg-neg | 34 (19) | 131 (32) | 34 (30) | |
| Not tested/inconclusive | 10 (6) | 35 (8) | 7 (6) | |
| Conditioning regimen intensity | <.001 | |||
| Myeloablative | 99 (56) | 246 (59) | 65 (58) | |
| Reduced intensity | 46 (26) | 119 (29) | 33 (29) | |
| Nonmyeloblative | 24 (15) | 47 (11) | 14 (13) | |
| Missing | 4 (2) | 1 (<1) | 0 | |
| Stem cell source | <.001 | |||
| Bone marrow | 14 (8) | 123 (30) | 21 (19) | |
| Peripheral blood | 162 (92) | 290 (70) | 91 (81) | |
| GVHD prophylaxis | <.001 | |||
| None | 1 (1) | 1 (<1) | 1 (1) | |
| FK506+MTX+-oth | 57 (32) | 198 (48) | 45 (40) | |
| FK506+-oth | 30 (17) | 63 (15) | 28 (25) | |
| CsA+MTX+-oth | 40 (23) | 91 (22) | 26 (23) | |
| CsA+-oth | 46 (26) | 50 (12) | 11 (10) | |
| Other | 2 (1) | 10 (2) | 1 (1) | |
| Anti-thymocyte globulin therapy | <.001 | |||
| No | 158 (90) | 306 (74) | 82 (73) | |
| Yes | 18 (10) | 107 (26) | 30 (27) | |
| Year of transplant | .01 | |||
| 2002 | 38 (22) | 47 (11) | 14 (13) | |
| 2003 | 23 (13) | 69 (17) | 22 (20) | |
| 2004 | 37 (21) | 81 (20) | 19 (17) | |
| 2005 | 44 (25) | 91 (22) | 32 (29) | |
| 2006 | 34 (19) | 125 (30) | 25 (22) | |
| Median (range) follow-up of survivors, mo | 50 (3-96) | 46 (6-87) | 39 (9-83) | |
| Total number died | 107 | 253 | 82 |
ch., chromosome; CsA, cyclosporin; F, female; FK506, tacrolimus; M, male; MTX, methotrexate; neg, negative; oth, other; pos, positive.
χ-square test.
Wilcoxon scores test.
Missing = 114.
In 80% of patients, the FAB class did not change from diagnosis to transplant, and in 9%, the FAB progressed to an advanced category.
Missing = 116.